Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.
The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.
News
Springer is delighted to announce a new memo inOncology SPECIAL ISSUE congress report from this years ASCO!
Congress Report ASCO 2018
The annual meeting of the American Society of Clinical Oncology took place June 1-5, 2018, in Chicago. Highlights included presentations about new insights into immunotherapy, the relevance of immune checkpoint blockade for treatment, new data on EGFR-directed TKIs and treatment of ALK-positive disease. The report also includes an Interview with Barbara Melosky titled “The sequencing question remains”.
Preceptorship Cologne – Lung Cancer International Preceptorship
Springer, The University Hospital of Cologne and the Center for Integrated Oncology Köln-Bonn held the Lung Cancer International Preceptorship on the 1st and 2nd February 2018, in Cologne (Germany). This preceptorship was addressed to medical oncologists involved in the care of patients with lung cancer. This report summarizes presentations that were given during…
Expert interviews at ASCO 2018
Edward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls pf liquid biopsies.
Barbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.